An Insight into Pandemic COVID-19: Structure, Epidemiology and Therapeutics

Author(s): Shanthipriya Ajmera*, Ranjitha H. Bommanna, Divya Ajmeera, Jayasree Dasyam, Ramchander Merugu

Journal Name: Current Biotechnology

Volume 10 , Issue 1 , 2021


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

The coronaviruses are enveloped viruses with a positive-sense ssRNA genome, possess helical symmetry, and belongs to the family Coronaviridae. They cause mild to lethal respiratory tract infections in both mammals and birds. The more pathogenic coronaviruses cause SARS, MERS, and COVID-19. The recent coronavirus outbreak was first discovered in December 2019. Subsequently, the disease has been declared as a pandemic by The World Health Organization (WHO). The virus is named Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the disease is now called COVID-19 [Coronavirus disease 2019]. The primary route of the virus spread between people is through close contact where a healthy person inhales the respiratory droplets from an infected person either by cough or sneezing. More than 2 million confirmed cases are reported globally. The US has the world's largest number of COVID-19 cases followed by European countries. As of April 18, 2020, 2 074 529 confirmed, and 139 378 deaths were reported. Presently, there is no specific drug or vaccine that is approved to treat SARS-CoV-2. The practice of hygienic measures such as frequent hand wash, use of masks, and social distancing would prevent the spread of the disease. This review focuses on a brief description of the viral structure and its multiplication, epidemiology and therapeutics with a special mention on the nanotechnology approach to combat covid-19. This review describes briefly the SARS-CoV-2 viral structure and its multiplication, epidemiology and therapeutics.

Keywords: COVID-19, SARS-CoV-2, viral structure, multiplication site, entry of the virus, therapeutics, practice hygiene measures, prevention.

[1]
Zhu N, Zhang D, Wang W, et al. China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020; 382(8): 727-33.
[http://dx.doi.org/10.1056/NEJMoa2001017] [PMID: 31978945]
[2]
Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395(10223): 507-13.
[http://dx.doi.org/10.1016/S0140-6736(20)30211-7] [PMID: 32007143]
[3]
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223): 497-506.
[http://dx.doi.org/10.1016/S0140-6736(20)30183-5] [PMID: 31986264]
[4]
Guan WJ, Ni ZY, Hu Y, et al. China Medical Treatment Expert Group for COVID-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382(18): 1708-20.
[http://dx.doi.org/10.1056/NEJMoa2002032] [PMID: 32109013]
[5]
Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020; 323(13): 1239-42.
[6]
de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol 2016; 14(8): 523-34.
[http://dx.doi.org/10.1038/nrmicro.2016.81] [PMID: 27344959]
[7]
Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020; 8(4): 420-2.
[http://dx.doi.org/10.1016/S2213-2600(20)30076-X] [PMID: 32085846]
[8]
Hui DS, I Azhar E, Madani TA, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis 2020; 91: 264-6.
[http://dx.doi.org/10.1016/j.ijid.2020.01.009] [PMID: 31953166]
[9]
Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020; 579(7798): 270-3.
[http://dx.doi.org/10.1038/s41586-020-2012-7] [PMID: 32015507]
[10]
Lan J, Ge J, Yu J, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 2020; 581(7807): 215-20.
[http://dx.doi.org/10.1038/s41586-020-2180-5] [PMID: 32225176]
[11]
Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis.Coronaviruses. New York, NY: Humana Press 2015; pp. 1-23.
[http://dx.doi.org/10.1007/978-1-4939-2438-7_1]
[12]
Wu F, Zhao S, Yu B, et al. Author Correction: A new coronavirus associated with human respiratory disease in China. Nature 2020; 580(7803): E7.
[http://dx.doi.org/10.1038/s41586-020-2202-3] [PMID: 32296181]
[13]
Hoffmann M, Kleine-Weber H, Krüger N, Mueller MA, Drosten C, Pohlmann S. The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. bioRxiv 2020.
[http://dx.doi.org/10.1101/2020.01.31.929042]
[14]
Wang N, Shang J, Jiang S, Du L. Subunit vaccines against emerging pathogenic human coronaviruses. Front Microbiol 2020; 11: 298.
[http://dx.doi.org/10.3389/fmicb.2020.00298] [PMID: 32265848]
[15]
Mackenzie JS, Smith DW. COVID-19: a novel zoonotic disease caused by a coronavirus from China: what we know and what we don’t. Microbiol Aust 2020; 41(1): 45-50.
[http://dx.doi.org/10.1071/MA20013] [PMID: 32226946]
[16]
Guo YR, Cao QD, Hong ZS, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak–an update on the status. Mil Med Res 2020; 7(1): 1-10.
[http://dx.doi.org/10.1186/s40779-020-00240-0] [PMID: 31928528]
[17]
Backer JA, Klinkenberg D, Wallinga J. Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travelers from Wuhan, China. Euro Surveill 2020; 25(5): 20-62.
[http://dx.doi.org/10.2807/1560-7917.ES.2020.25.5.2000062] [PMID: 32046819]
[18]
Liu Y, Gayle AA, Wilder-Smith A, Rocklöv J. The reproductive number of COVID-19 is higher compared to SARS coronavirus. J Travel Med 2020; 27(2)taaa021.
[http://dx.doi.org/10.1093/jtm/taaa021] [PMID: 32052846]
[19]
Shi J, Wen Z, Zhong G, et al. Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2. Science 2020; 368(6494): 1016-20.
[http://dx.doi.org/10.1126/science.abb7015] [PMID: 32269068]
[20]
Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV) Nat Rev Drug Discov. 2020; 19: 149-50.
[http://dx.doi.org/10.1038/d41573-020-00016-0]
[21]
Zumla A, Chan JF, Azhar EI, Hui DS, Yuen KY. Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov 2016; 15(5): 327-47.
[http://dx.doi.org/10.1038/nrd.2015.37] [PMID: 26868298]
[22]
Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30(3): 269-71.
[http://dx.doi.org/10.1038/s41422-020-0282-0] [PMID: 32020029]
[23]
Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 2020; 14(1): 72-3.
[http://dx.doi.org/10.5582/bst.2020.01047] [PMID: 32074550]
[24]
Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020; 71(15): 732-9.
[http://dx.doi.org/10.1093/cid/ciaa237] [PMID: 32150618]
[25]
Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res 2020; 178104787.
[http://dx.doi.org/10.1016/j.antiviral.2020.104787] [PMID: 32251768]
[26]
Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. J Clin Invest 2020; 130(4): 1545-8.
[http://dx.doi.org/10.1172/JCI138003] [PMID: 32167489]
[27]
Bharat Biotech's COVID vaccine 1st [27] in India to get approval for human trials The Indian Express 30 June. 2020.
[28]
Aljofan M, Gaipov A. COVID-19 Treatment: The Race Against Time. Electron J Gen Med 2020; 17(6): em227.
[http://dx.doi.org/10.29333/ejgm/7890]
[29]
Nanotechnology versus coronavirus. Nat Nanotechnol 2020; 15(8): 617.
[http://dx.doi.org/10.1038/s41565-020-0757-7] [PMID: 32764720]
[30]
Hosseinkhani H, Chen Y-R, He W, Hong P-D, Yu D-S, Domb AJ. Engineering of magnetic DNA nanoparticles for tumor-targeted therapy. J Nanopart Res 2013; 15: 1345-55. http://dx.doi.org/10.1007/s11051-012-1345-z.
[31]
Hosseinkhani H. Nanomaterials in advanced medicine. Wiley J. Sons. 2019..
[32]
Steinman NY, Campos LM, Feng Y, Domb AJ, Hosseinkhani H Cyclopropenium nanoparticles and gene transfection in cells Pharmaceutics 2020; 12: 768-79.
[http://dx.doi.org/10.3390/pharmaceutics12080768]
[33]
Hosseinkhani H, Domb AJ Biodegradable polymers in gene silencing technology Polym Adv Technol 2019; 30(10): 2647-55.
[http://dx.doi.org/10.1002/pat.4713]
[34]
Abedini F, Ebrahimi M, Roozbehani AH, Hosseinkhani H, Domb J Overview on natural hydrophilic polysaccharide polymers in drug delivery Polym Adv Technol 2018; 29(10): 2564-73.
[http://dx.doi.org/10.1002/pat.4375]
[35]
Abedini F, Ebrahimi M, Hosseinkhani H. Technology of RNA Interference in Advanced Medicine. MicroRNA 2018; 7(2): 74-84.
[http://dx.doi.org/10.2174/2211536607666180129153307] [PMID: 29380708]
[36]
Mottaghitalab F, Rastegari A, Farokhi M, et al. Prospects of siRNA applications in regenerative medicine. Int J Pharm 2017; 524(1-2): 312-29.
[http://dx.doi.org/10.1016/j.ijpharm.2017.03.092] [PMID: 28385649]
[37]
Ghadiri M, Vasheghani-Farahani E, Atyabi F, Kobarfard F, Mohamadyar-Toupkanlou F, Hosseinkhani H. Transferrin-conjugated magnetic dextran-spermine nanoparticles for targeted drug transport across blood-brain barrier. J Biomed Mater Res A 2017; 105(10): 2851-64.
[http://dx.doi.org/10.1002/jbm.a.36145] [PMID: 28639394]
[38]
Ghadiri M, Vasheghani-Farahani E, Atyabi F, Kobarfard F, Hosseinkhani H. In-Vitro Assessment of Magnetic Dextran-Spermine Nanoparticles for Capecitabine Delivery to Cancerous Cells. Iran J Pharm Res 2017; 16(4): 1320-34.
[PMID: 29552044]
[39]
Gholivand MB, Mohammadi-Behzad L, Hosseinkhani H. Application of a Cu-chitosan/multiwalled carbon nanotube film-modified electrode for the sensitive determination of rutin. Anal Biochem 2016; 493: 35-43.
[http://dx.doi.org/10.1016/j.ab.2015.08.033] [PMID: 26408813]
[40]
Alibolandi M, Abnous K, Sadeghi F, Hosseinkhani H, Ramezani M, Hadizadeh F. Folate receptor-targeted multimodal polymersomes for delivery of quantum dots and doxorubicin to breast adenocarcinoma: In vitro and in vivo evaluation. Int J Pharm 2016; 500(1-2): 162-78.
[http://dx.doi.org/10.1016/j.ijpharm.2016.01.040] [PMID: 26802496]
[41]
Mottaghitalab F, Farokhi M, Shokrgozar MA, Atyabi F, Hosseinkhani H. Silk fibroin nanoparticle as a novel drug delivery system. J Control Release 2015; 206: 161-76.
[http://dx.doi.org/10.1016/j.jconrel.2015.03.020] [PMID: 25797561]
[42]
Alibolandi M, Abnous K, Ramezani M, Hosseinkhani H, Hadizadeh F. Synthesis of AS1411-aptamer-conjugated CdTe quantum dots with high fluorescence strength for probe labeling tumor cells. J Fluoresc 2014; 24(5): 1519-29.
[http://dx.doi.org/10.1007/s10895-014-1437-5] [PMID: 25172439]
[43]
He W, Hosseinkhani H, Mohammadinejad R, et al Polymeric nanoparticles for therapy and imaging Polym Adv Technol 2014; 25(11): 1216-25.
[http://dx.doi.org/10.1002/pat.3381]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 10
ISSUE: 1
Year: 2021
Published on: 11 December, 2020
Page: [13 - 17]
Pages: 5
DOI: 10.2174/2211550109999201211203631
Price: $65

Article Metrics

PDF: 220
HTML: 1